Pharmaceutical Insights · Steven Li
Source-based perspectives on CMO/CDMO projects, technology transfer, contract-manufacturing quality governance and cross-border partnerships.
A source-bound monitor of recent WHO, Nature and NEJM anti-infective evidence, separating policy, discovery and clinical stages from company or project conclusions.
Read the international evidence monitor →A source-bound guide to using Haikou biopharma ecosystem information for initial partner research—without treating it as company, site, policy or project evidence.
Read the ecosystem diligence guide →An official-source guide to the Hainan pharmaceutical-policy environment, the limited scope of special measures and the project-level checks that overseas partners should complete before drawing conclusions.
Read the Hainan policy diligence guide →A source-based explanation of why China no longer issues separate drug GMP certificates, what GMP evidence to verify now, and how to read product-specific CoPP without overclaiming.
Read the GMP and CoPP guide →A dated company-name query snapshot of 147 product/form/strength/approval-number/marketState combinations returned by the official NHSA public drug-data service. It is not a supply list or current product decision.
Read the public-record snapshot →A source-bounded guide to reading dated official product records before a non-confidential CMO/CDMO enquiry. It does not confirm current approval, supply, capacity or project fit.
Read the full guide →A bounded guide to using a supplied product catalogue as a dosage-form and therapeutic-area screening map for non-confidential cooperation discussions. It does not confirm current approval, availability, supply or project fit.
Read the full guide →A source-based checklist for transferring analytical procedures to a pharmaceutical CMO/CDMO, covering scope, strategy, protocol, acceptance criteria, laboratory readiness and lifecycle control. It does not establish project acceptance, site readiness or regulatory approval.
Read full article →A source-based RFP checklist for sterile injectable CMO/CDMO projects. It separates a non-confidential first screen from NDA diligence, clarifies target-market and quality assumptions, and makes the next decision gate explicit. It is not evidence that any facility or project is eligible, accepted or ready for supply.
Read full article →A source-based lyophilized-product CMO due-diligence guide covering product-to-cycle fit, sterile-process interfaces, analytical and stability evidence, and technology-transfer governance. A public platform statement is only an initial fit screen, not project acceptance, capacity or regulatory eligibility.
Read full article →Download lyophilized-product CMO checklist (PDF) →NMPA Announcement No. 134 (2025) makes a contract-manufacturing decision a controlled quality-and-technical process. This source-based checklist explains the early evaluation of MAH and product fit, technical-transfer feasibility, co-line risk, sterile-drug governance and quality-agreement interfaces. It is regulatory context, not evidence that any site or project is eligible.
Read full article →A source-record CMO audit checklist covering governance, investigations and CAPA, change control, technology transfer, supply reliability and a controlled audit decision record.
Read full article →Download CMO audit evidence checklist (PDF) →An NMPA-aligned China contract-manufacturer audit framework covering legal entity, site scope, product fit, technology transfer, co-manufacturing risk and agreements.
Read full article →Hainan’s public measures offer policy context for research, localisation and cross-border cooperation involving imported innovative and improved new drugs. This source-based article explains the project questions that still require product-, site- and responsibility-level verification.
Read full article →An official Madagascar medicines list dated 16 September 2025 names Hainan Hailing Chemipharma in three sterile injectable entries. This is verifiable evidence of a public overseas registration footprint; it is not evidence of current sales, tender awards, market share or uninterrupted supply.
Read full article →Southeast Asia is geographically close to Hainan, but proximity alone does not create a durable pharmaceutical business. Sustainable cooperation requires national-market discipline, a clear allocation of regulatory and quality responsibilities, and stage-gated decisions from non-confidential screening through launch and lifecycle management.
Read full article →Technology transfer is a controlled product-lifecycle process, not a document handoff. A receiving site must be able to reproduce the product, process or analytical procedure against predefined specifications, with risks, responsibilities and acceptance criteria documented in advance.
Read full article →Cross-border CMO and CDMO programs need more than audits and certificates. They require a working quality-governance system that connects responsibilities, technical controls, data integrity, change management and escalation across organizations and jurisdictions.
Read full article →Sterile injectable CMO/CDMO selection cannot be reduced to a dosage-form match or a capacity statement. A viable project must align the product, process, facility, analytical package, quality governance, regulatory pathway, supply model and commercial timing through evidence-based stage gates.
Read full article →CMO, CDMO and technology transfer are not interchangeable labels. The right model depends on what is already established, what still needs to be developed, who will hold regulatory and quality responsibilities, and where routine commercial manufacture is intended to occur.
Read full article →Download 2-page decision brief (PDF) →A pharmaceutical quality agreement should translate legal and regulatory roles into an operating responsibility matrix. It must define who performs, reviews, approves, communicates and retains evidence for every quality-critical activity, while making clear that a contract does not transfer away statutory responsibility.
Read full article →A useful preliminary CMO/CDMO assessment does not require a formula, full dossier or patient data. It needs a concise non-confidential fact sheet covering dosage form, stage, target market, requested scope, scale, presentation, timeline and regulatory ownership, followed by phased disclosure after an NDA and controlled data-room plan.
Read full article →A practical sterile injectable CMO audit checklist: verify legal scope, product-to-train fit, lyophilized-product controls, quality systems and technology-transfer readiness.
Read full article →Download sterile CMO audit checklist (PDF) →A practical pharmaceutical outsourcing due-diligence checklist covering the named legal entity and site, product and target-market fit, quality and regulatory evidence, manufacturing and analytical readiness, supply continuity, governance, agreements and decision gates.
Read full article →Download pharmaceutical outsourcing due-diligence checklist (PDF) →Transfer readiness is not the number of files received. It is the receiving team’s ability to explain critical product knowledge, execute the process and methods, control materials and equipment, investigate variation and produce traceable evidence against agreed acceptance criteria.
Read full article →Download technology-transfer readiness checklist (PDF) →A project should be placed on hold when a critical uncertainty cannot be converted into a controlled task with an owner, evidence, acceptance criteria and a realistic decision date. Holding is not failure; it protects product quality, regulatory integrity, capital and trust.
Read full article →CMO · CDMO · Technology Transfer